As a result, current gene delivery to the central nervous system (CNS) continues to be a challenge, Pooler told ScienceBoard.net at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC. However, Sangamo's adeno-associated virus (AAV) capsids are designed to overcome the blood-brain barrier, ensuring CNS access while minimizing exposure to a patient's preexisting anti-AAV antibodies.

"What we want to do is engineer novel capsids that can penetrate into the brain," Pooler said. "Sangamo scientists developed a novel platform that I'm really excited about. It's called SIFTER, Selection In vivo for Transduction and Expression of RNA. And what's really exciting about this part is the expression. We know that AAV can travel around the body but it's not enough just for it to get to the target tissue. It also has to get inside the cell and express the therapeutic payload. In our case, it's the zinc fingers."

Two new novel capsids were discovered using the SIFTER technique by Sangamo's David Ojala, PhD, senior scientist for AAV engineering. At ASGCT 2022, Ojala presented pre-clinical data on a study of the genetically engineered AAV capsid platform for delivery to the CNS after cerebrospinal fluid administration.

A poster presentation at the meeting also discussed the first applications of the SIFTER platform to Sangamo's blood-brain barrier program, which is "looking to deliver intravenously in order to achieve widespread brain delivery," Pooler said.

Watch the video below to learn more.

Decibel Therapeutics develops treatments to restore and improve hearing, balance
Decibel Therapeutics is helping to break down the barriers to understanding the molecular pathways and cell physiology inside the inner ear by integrating...

Mustang Bio focuses on CD20 antigen for CAR T-cell therapy
Biopharmaceutical company Mustang Bio is focused on a CD20-targeted autologous chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma,...

Lexeo to start phase I/II clinical trial for patients with FA cardiomyopathy
Gene therapy company Lexeo Therapeutics in 2022 plans to launch a phase I/II clinical trial of its adeno-associated virus-based therapy designed to intravenously...

Graphite Bio sees its gene editing tech as step above CRISPR
While the use of CRISPR is an effective gene editing tool on its own, Dr. Josh Lehrer, CEO of Graphite Bio, contends that the technology doesn’t correct...

COVID-19 mRNA-based vaccines benefit from decades of research
25 years ago Dr. Drew Weissman, PhD, an infectious disease expert at Penn Medicine, and RNA biologist Kati Kariko, PhD, began their collaboration in...

Genenta Science reports preliminary results of Temferon-glioblastoma study
Biotech company Genenta Science is developing a proprietary hematopoietic stem cell gene therapy, Temferon, for the treatment of a variety of solid tumor...

Next-generation AAV capsids hold key to developing life-changing therapies
Voyager Therapeutics’ discovery platform is identifying novel capsids targeting desired cells and tissues with greater specificity, at lower doses, and...

How to address challenges in producing AAV vectors
There are challenges in producing sufficient quantities of gene therapy products, particularly when it comes to adeno-associated virus (AAV) vectors,...

Atsena Therapeutics’ gene therapy takes aim at childhood blindness
In an interview with ScienceBoard.net, Patrick Ritschel, CEO of Ophthalmology-based gene therapy company Atsena Therapeutics, shared an overview...

Omega Therapeutics looks to tap 'nature's operating system' to control gene expression
Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation,...

Delivery of gene therapies remains a key challenge
Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge,...

Next evolution of CAR T-cell therapy is solid tumors
While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the...